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Background: The FlutterVRP1 combines high frequency oscillation and positive expiratory
pressure (PEP).
Objective: To separately evaluate the effect of the FlutterVRP1 components (high frequency
oscillation and PEP) on mucus transportability in patients with bronchiectasis.
Methods: Eighteen patients with bronchiectasis received sessions with the FlutterVRP1 or PEP
for 30 min daily in a randomized, crossover study. The treatment duration was four weeks with
one of the therapies, one week of a “wash-out” period and followed by four more weeks with
the other treatment. Weekly secretion samples were collected and evaluated for mucociliary
relative transport velocity (RTV), displacement in a simulated cough machine (SCM) and
contact angle measurement (CAM). For the proposed comparisons, a linear regression model
was used with mixed effects with a significance level of 5%.
Results: The FlutterVRP1 treatment resulted in greater displacement in SCM and lower CAM
when comparing results from the first (9.6  3.4 cm and 29.4  5.7, respectively) and fourth
weeks of treatment (12.44  10.5 cm and 23.28  6.2, respectively; p < 0.05). There was no
significant difference in the RTV between the treatment weeks for either the FlutterVRP1 or
PEP.
Conclusion: The use of the FlutterVRP1 for four weeks is capable of altering the respiratory
secretion transport properties, and this alteration is related to the high frequency oscillation
component.
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The FlutterVRP1 components on secretion transport 1317Introduction ProtocolBronchiectasis is a respiratory pathway disease with diverse
etiologies that is pathologically characterized by abnormal
and permanent dilated airways1,2 and principally caused by
the perpetuation of inflammatory processes induced by
frequent bacterial infections. This results in an alteration
of the ciliated epithelial lining and compromised muco-
ciliary clearance effectiveness.3
The damage to mucociliary clearance is associated with
thicker mucous production and, therefore, results in less
transport that favors the hypersecretory state observed in
these patients1; this can also exacerbate and increase
secretion production periods resulting in significant reper-
cussions for the individual.4
Beyond medication and/or surgical treatment, patients
with bronchiectasis also have indications for physiother-
apeutic treatment, which constitutes an important part of
the treatment regimen. The patients demonstrate difficulty
with mucous elimination and transport and can experience
benefits from respiratory physical therapy,5 which has the
goal of increasing the removal of respiratory pathway
secretions and consequently decreases blockages to
improve pulmonary ventilation and gas exchange.6
One of the instruments frequently used for respiratory
physical therapy is the FlutterVRP1 (VarioRaw S.A,
Switzerland), which is a simple, small piece of equipment
similar to a pipe that has a stainless steel ball within it and
combines two techniques: positive expiratory pressure and
high frequency oscillations, adjuvants for the treatment
and prevention of alveolar collapse and the elimination of
pulmonary secretions.
Some previous studies have demonstrated beneficial
effects after the use of this device in patients with
bronchiectasis.7e9 However, it is not clear if the mechanism
of action is related to the combination of PEP and high
frequency oscillation techniques or only one of these
components.
Therefore, the present study was designed to evaluate
the FlutterVRP1 effects (VarioRaw S.A, Switzerland) on
mucous transportability in patients with bronchiectasis in
order to separately identify the effects of the PEP and high
frequency oscillation components.Material and methods
Patients were selected for this study if they were clinically
stable with a diagnosis of bronchiectasis that was not due to
cystic fibrosis, as defined by a complete clinical history,
physical examination and confirmed by CT scan.
Patients were excluded from the study if they did not
demonstrate a sufficient respiratory secretion quantity for
the analysis or if they had developed any respiratory
infection in the four weeks prior to the study or during the
protocol.
This study was registered in the “Protocol Registration
System e ClinicalTrials.gov” (NCT01209546) and the
participating individuals were informed about all stages of
the research and signed an informed consent form
approved by the local ethics committee (no 6007/2007).The patients received FlutterVRP1 or PEP exercise
sessions daily for 30 min each day in a randomized, cross-
over study. Each patient received treatment with one of
the therapies for four weeks, which was randomly deter-
mined by a drawing, followed by one week of a “wash-out”
period10,11 and then an additional four more weeks with the
other treatment modality.10
The exercises were performed in the seated position,
and patients were instructed to perform long and quiet
expirations during the treatment. In order to evaluate the
technique used by the patients and to perform the secre-
tion collection, a physiotherapist supervised the patients
twice per week. During all other days, the patients
completed the exercises without supervision and were
instructed to record information daily regarding the
number of pauses while using the device or other relevant
observations.
The FlutterVRP1 (Flutter) protocol used the equipment
without modifications. The PEP protocol used the Flut-
terVRP1 device without the stainless steel ball inside and
after occluding as many orifices as was necessary to
produce a positive expiratory pressure equivalent to the
pressure reached by patients when using the FlutterVRP1
with the stainless ball.4 Pressure was measured with
a manometer connected to an orifice located in the inferior
portion of the device.4
Prior to completing the protocol, the participants were
instructed to continue their medications according to
instructions with the exception of mucolytics and were
evaluated with regards to arterial pressure, cardiac
frequency, partial oxygen saturation and respiratory
frequency.
The respiratory secretion studied was expectorated
spontaneously by the patient but always supervised by the
physiotherapist.Evaluated respiratory secretion parameters
Relative transport velocity measured on the frog palate
Frogs (Rana Catesbiana) had their palates removed
following decapitation and were maintained at 4 C for 48 h
to collect the mucous. Small amounts of patient mucous
were removed from a plastic tube and were submerged in
ether to remove excess Vaseline and then deposited on the
palate. The sample displacement was observed using
a stereomicroscope with an 8 magnification lens (Carl
Zeiss, Stemi1000-Germany), and the transport time was
recorded with the use of a chronometer (Herweg-8904-
Brazil).9 The results were expressed as relative transport
velocity compared to the average of five experimental
mucous transport velocity measurements for the frog
(average of the summed velocity of the initial and final frog
speeds for the experimental mucous evaluation).
Simulated cough machine transport
Analysis of the cough machine mucous transport was
completed according to the model described by King
et al.12 and adopted by the Heart Institute Precision Insti-
tute e Incor e SP. The model was composed of a pressure
Table 1 Description of the RTV, CSM and CAM for each treatment (Flutter and PEP) and week.
Flutter (HFO þ PEP) PEP (PEP only)
Week Variable Average DP Week Variable Average DP
1 RTV 1.04 0.44 1 RTV 1.18 0.3
SCM cm* 9.6 3.41 SCM cm 11.12 4.24
CAM* 29.39 5.74 CAM 27.9 7.04
2 RTV 1 0.23 2 RTV 1.13 0.42
SCM cm 10.03 3.31 SCM cm 11.25 5.15
CAM 24.01 5.72 CAM 28.2 5.6
3 RTV 1 0.16 3 RTV 1.07 0.3
SCM cm 12.17 4.79 SCM cm 11.03 4.47
CAM 27.76 5.2 CAM 26.59 5.55
4 RTV 1.1 0.29 4 RTV 1.26 0.36
SCM cm* 12.44 3.74 SCM cm 11.19 3.75
CAM* 23.28 6.21 CAM 28.81 5.56
*p < 0.05.
Fig. 1 Graphical representation of the relative transport
velocity values in the first and forth weeks of Flutter and PEP
therapy.
1318 J. Tambascio et al.source, a solenoid valve and a simple scheme of airways,
represented by a dry acrylic cylinder measuring 30 cm in
length and 4 mm in internal diameter, with the three
elements connected in a series. When the cough simulator
machine was activated, the timing device controlled
opening of the solenoid for 1 s, allowing the exit of air at
4.2 kg f/cm2 of pressure, thus moving the secretion
sample.4 Each mucous sample was tested five times and the
average of these five displacements was used.
Contact angle measurement
The angle, in degrees, formed between the mucous and the
glass surface was considered the contact angle and was
measured using a goniometer with a 20 magnification
lens. The glass surface used for these analyses was treated
with sulphochromic acid to remove any electrical charge.
The sample was evaluated five times and the average of
these measurements was used.4
Statistical analysis
To evaluate the objectives, a linear regression model with
mixed effects was used (random and fixed effect) using
a significance level established at 5%.
A possible sequential effect was initially evaluated and
subsequently compared to the results obtained after
application of the two techniques.
Results
There were 30 patients that were selected to participate in
the study; six of these did not demonstrate any secretion
during the analysis protocol and six experienced respiratory
tract infections during the activity period. Therefore, 18
patients participated in and completed the protocol.
Of the 18 patients, 13 were female and five were male
with an average age of 51.7  18.4 years. In regards to
pulmonary function, one participant demonstrated values
within normal ranges (VEF1/CVF > 0.7 and VEF1 of 95%) and
17 demonstrated airway obstruction (VEF1/CVF < 0.7),with three with VEF1 varying from 81 to 83%, nine with VEF1
varying from 62 to 77%, four with VEF1 varying from 31 to
47% and one with VEF1 of 29%.
The average positive expiratory pressure achieved by
the patients was 15.7 cmH2O, with a range of 4e32 cmH2O.
Table 1 shows the results of the relative transport
velocity (RTV), displacement in simulated cough machine
(CSM) and contact angle measurement (CAM) for each
treatment and week. The initial statistical analysis
demonstrated that there was no sequential effect in the
treatment of the patients, and the results were analyzed
comparing the initial values between the PEP and Flutter
VRP1 groups.
In regards to the relative transport velocity, there was
no statistically significant difference between the treat-
ment weeks or type of treatment (Fig. 1).
When the displacement in the simulated cough machine
was evaluated, there was increased displacement for the
values obtained in the fourth week (12.44  10.5 cm)
compared to those obtained in the first week (9.6  3.4 cm)
Fig. 2 Graphical representation of the displacement values
in the simulated cough machine (SCM) during the first and the
fourth weeks of Flutter and PEP therapy.
The FlutterVRP1 components on secretion transport 1319of Flutter therapy (p < 0.05). There was no difference
when the displacement values were compared between the
PEP therapy treatment weeks (Fig. 2).
In regards to the contact angle measurement (CAM),
there was a decrease in the values obtained in the first
(29.39  5.7) when compared with the fourth week
(23.28  6.2) when using the Flutter therapy (p > 0.05).
There was no difference in the contact angle values when
comparing between treatment weeks f PEP (Fig. 3).
Discussion
In this study, the relative transport velocity on a frog palate
(RTV), the displacement on a simulated cough machine
(SCM) and the contact angle measurement (CAM) of respi-
ratory secretions were measured in patients with bronchi-
ectasis that received oscillating positive expiratoryFig. 3 Graphical representation of the contact angle
measurement (CAM) values in first and fourth weeks of Flutter
and PEP therapy.pressure treatment (Flutter therapy) and positive expira-
tory pressure (PEP therapy) via the use of the FlutterVRP1
device. The protocol included four weeks of treatment with
one of the therapies, one week of a “wash-out” period and
four additional weeks with the other treatment modality.
The results revealed a decreased contact angle and
increased displacement of expectorated secretions
submitted at the end of the fourth week of Flutter therapy
treatment.
On the other hand, the use of PEP therapy, which, in this
protocol, had the purpose of differentiating the two
components involved in the FlutterVRP1mechanism
(oscillation þ PEP) but also constitutes one type of physical
therapy technique for secretion removal (PEP or EPAP), did
not reveal any changes in the properties of respiratory
secretion transport during the same period.
To our knowledge, this is the first study that has
demonstrated an improvement in respiratory secretion
transport after exercises with FlutterVRP1 in patients with
bronchiectasis. The increased displacement measured by
coughing and a reduced contact angle can be attributed to
thixothropic flow, a property of mucous that results in
reduced viscosity when submitted to oscillation.13 This
effect had been demonstrated by App et al. (1998)10 and
Ramos et al. (2009)9 in patients with bronchiectasis and
cystic fibrosis, respectively.
Early use of oscillation equipment to aid in secretion
removal came from experimental studies in dogs that
demonstrated better secretion transport after oral or
thoracic oscillations with the greatest effect in the
13e15 Hz frequency band.14,15 With the FlutterVRP1,
in vitro studies have obtained decreased mucus rigidity
that is more easily transported through airways after the
application of high frequency oscillations, resulting in the
hypothesis that these oscillation frequencies may be
capable of breaking the macromolecular bonds in the
mucus.16,17
App et al. (1998),10 in a similar protocol (four week,
crossover study), evaluated respiratory secretions after
using the FlutterVRP1 device or autogenic drainage tech-
niques in patients with cystic fibrosis. The authors reported
reduced viscosity and increased calculated ciliary transport
and cough treatment transport indices after using the
FlutterVRP1.
Previously, in cystic fibrosis, Konstan et al. (1994)18
evaluated the effectiveness of FlutterVRP1 device by
comparing the results with conventional respiratory phys-
ical therapy techniques (voluntary cough or postural
drainage) and reported a greater sputum expectorated
volume with the use of the FlutterVRP1 device. However,
in the same year, Pryor et al. (1994)19 compared results of
the use of the FlutterVRP1 device and an active respira-
tion cycle and observed a greater expectorate volume with
the active respiration cycle.
In regards to patients with bronchiectasis, some previous
studies have studied the effectiveness of the FlutterVRP1
in relation to the expectorate secretion volume,7 relative
velocity on the frog palate,4,8,9 displacement in the simu-
lated cough machine,4,8,9 contact angle4,9 and respiratory
secretion viscosity.8,9 However, studies by Antunes (2001)7
and Valente (2004)4 did not demonstrate beneficial results
after the use of the FlutterVRP1.
1320 J. Tambascio et al.Pires et al. (2004),8 in a case study with results from only
one patient and only three therapy sessions, observed
improved ciliary transport, cough transport and respiratory
secretion viscosity after the use of the same equipment
compared to thoracic percussion.
Ramos et al. (2009)9 have already demonstrated
decreased respiratory secretion viscosity after the use of
a FlutterVRP1 for only one day. However, the viscosity
alteration did not demonstrate improved transport indices
for ciliary or cough transport, which, in reality, leaves
doubts about the clinical effectiveness of the device. Those
results confirm the findings of Valente et al.4 and the
present study, neither of which observed acute effects
from FlutterVRP1 therapy either after a single 40-min
session4 or after one or two weeks of therapy (present
study).
It is likely that our results are related to the fact that we
employed the technique daily during the four weeks of
proposed treatment, whereas others have studied the
effects with a maximum of only four FlutterVRP1 sessions
in bronchiectasis patients.4,7e9
Although we did not evaluate respiratory secretion
viscosity, our results indirectly suggest physical property
changes due to the fact that use of the FlutterVRP1 device
over a four week period was capable of modifying secretion
properties, as demonstrated by the decreased contact
angle and improved cough transport. These alterations
favor secretion removal in these patients with damaged
mucociliary transport that use coughing as a primary
clearance mechanism.
The lack of changes in the relative transport velocity,
representative of ciliary transport function, is consistent
with previous work4,9 and may be related to the fact that
the relative transport velocity in our samples was within
the normal range, varying from 1.0e1.1.20
Another hypothesis is that patients with chronic hyper-
secretion initially have mucociliary transport damage, but
with changes in cough transport. With disease progression,
the cough transport also becomes damaged.21,22 It is
possible that the changes induced by the FlutterVRP1
exercises promote a partial reversion of these alterations,
thereby demonstrating improved cough transport but not
improved ciliary transport.
PEP therapy, as previously mentioned, also represents
a secretion removal technique and, in this study, was used
to isolate the mechanisms used by FlutterVRP1 therapy
that correlated with the improvement in respiratory
secretion transport. However, the lack of significant results
for this technique implies that the four week period was not
enough to modify the secretion transport properties. In
other words, the factor that was capable of influencing
transport properties is more related to the oscillation
technique that the FlutterVRP1 offers than with positive
expiratory pressure.
The average attained expiratory pressure during this
protocol was 15.7 cmH2O with a range of 4e32 cmH2O. We
believe that this variation did not interfere with our results
because the positive expiratory pressure level used was
similar to that produced by the FlutterVRP1. This strategy
was used to separately identify the involved mechanisms in
the selected equipment. Moreover, the authors that eval-
uated the FlutterVRP1 device with controlled expiratorypressures did not find significant results between transport
index values.9
These results allow us to conclude that the use of the
FlutterVRP1 device for four weeks is capable of modifying
respiratory secretion transport properties and that this
alteration is more closely related to the high frequency
oscillation component of the treatment.Conflict of interest
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